Format

Send to

Choose Destination
Trends Immunol. 2008 Dec;29(12):624-32. doi: 10.1016/j.it.2008.09.004. Epub 2008 Oct 25.

Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.

Author information

1
Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA.

Abstract

Allogeneic hematopoietic cell transplantation (alloHCT) represents the only curative therapy for several hematologic malignancies, and shows promise as a nascent treatment modality for select solid tumors. Although the original goal of alloHCT was hematopoietic reconstitution after sub-lethal chemoradiotherapy, recognition of a profound donor lymphocyte-mediated graft-versus-leukemia (GVL) or graft-versus-tumor (GVT) effect has shifted the paradigm from pre-transplant cytoreduction to tumor control via donor lymphocytes. In human leukocyte antigen (HLA)-compatible alloHCT, GVL and GVT reactions are induced primarily by donor T-cell recognition of minor histocompatibility antigens (mHAgs). Here we review the literature regarding mHAg-specific T cells in GVL and GVT reactions, and discuss the prospects of exploiting mHAgs as immunotherapeutic targets.

PMID:
18952501
PMCID:
PMC2593397
DOI:
10.1016/j.it.2008.09.004
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center